Background:
Congenital afibrinogenemia is an autosomal recessive bleeding disorder referring to the total absence of fibrinogen measured by an antigenic assay. The commonest manifestation of the disease is bleeding from mucosal…
“From Principles to Practice: Preparing for the Advent of Gene Therapy” represents the newest educational activity in Medscape’s series “Clinical Advances in Gene Therapy for Hemophilia.” Presented through a collaboration between Medscape and the…
In case you were unable to join us for our Wednesday Webinar Series on January 20th you can view it here. Listen to the NHF Public Policy Team discuss the upcoming Washington Days and advocacy issues facing the bleeding disorders community.…
In case you were unable to join us for our Wednesday Webinar Series on January 27th you can view it here. Listen to Kollet Koulianos from our Payer Relations team discuss and explain the importance of Accumulator Adjustors.
Register…
In case you were unable to join us for our Wednesday Webinar Series on January 13th you can view it here. Listen to NHF president and CEO, Leonard A. Valentino, MD, for New Directions for 2021: State of the Foundation, as he shares…
Paulette Bryant, MD is a Pediatric Hematologist–Oncologist at the St. Jude Affiliate Clinic at Novant Health Hemby Children’s Hospital in Charlotte, NC. She serves as the Physician Lead of the Pediatric Hematology Division and is the Pediatric…
Objective:
The impact of hemophilia on working life, the ability to pursue a desired career or sustain full employment have been previously reported. The aim of this analysis was to seek a better understanding of hemophilia-…
CSL Behring has announced a voluntary pharmacy level product recall of one batch of Mononine Coagulation Factor IX (Human), a plasma-derived product used to treat hemophilia B. CSL Behring’s notification states, “Patients can continue…
en Español (function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s…
BioMarin recently announced positive updates from its ongoing phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. The trial currently includes 134 participants,…